Last updated: April 2026
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.
Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.
Quick Answer
- Studies on HBOT for PTSD symptoms show improvements in 40-60 treatments across pressures from 1.3 to 2.0 ATA Systematic review of HBOT for PTSD.
- A linear dose-response relationship was found for increased symptomatic improvement with higher cumulative oxygen doses, from 1002 to 11,400 atmosphere-minutes of oxygen Systematic review of HBOT for PTSD.
- In 30-39% of subjects, the highest oxygen doses were linked to a severe but reversible increase in emotional symptoms Systematic review of HBOT for PTSD.
- All seven randomized trials reviewed for PTSD were rated as good-highest quality by the PEDro scale Systematic review of HBOT for PTSD.
Hyperbaric Oxygen Therapy (HBOT) has shown promise in managing symptoms related to post-traumatic stress disorder (PTSD), which often includes chronic pain aspects, and has been explored for other neurological conditions like acute ischaemic stroke and traumatic brain injury. Research indicates that patients undergoing 40-60 HBOT treatments, at pressures between 1.3 and 2.0 ATA, experienced significant improvements in PTSD symptoms. These benefits were not just subjective; three studies observed changes in functional and anatomic brain imaging, suggesting a physiological basis for the improvements. Importantly, a linear dose-response relationship was identified, where higher cumulative oxygen doses, ranging from 1002 to 11,400 atmosphere-minutes of oxygen, correlated with greater symptomatic relief. While HBOT holds potential, it is crucial to note that 30-39% of subjects experienced a severe but reversible exacerbation of emotional symptoms at the highest oxygen doses.
What is Hyperbaric Oxygen Therapy (HBOT)?
Hyperbaric oxygen therapy (HBOT) involves patients breathing pure oxygen in a special pressurized chamber. This controlled environment allows for a greater amount of oxygen to dissolve into the body's blood, plasma, and other fluids, reaching tissues that might otherwise be starved of oxygen. The increased pressure helps oxygen travel more effectively throughout the body, promoting healing and reducing inflammation. While HBOT is recognized for specific medical conditions, its potential benefits for a broader range of complex conditions like chronic pain and various brain injuries are still under active investigation through clinical trials and systematic reviews.
The Science Behind Pressurized Oxygen
In a typical environment, we breathe air that is about 21% oxygen. During HBOT, the patient breathes 100% oxygen, often at pressures higher than sea level. For example, some studies use pressures ranging from 1.3 to 2.0 ATA (atmospheres absolute) Systematic review of HBOT for PTSD. This elevation in pressure means that more oxygen molecules are forced into the bloodstream and tissues. This super-oxygenated state can help repair damaged cells, fight certain infections, and support the body's natural healing processes. The goal is to deliver oxygen to areas that may have poor blood flow or are struggling to heal, which is a common issue in chronic pain states and neurological damage.
How HBOT Differs from Standard Oxygen Therapy
Standard oxygen therapy often involves delivering oxygen through a mask or nasal cannula at normal atmospheric pressure. HBOT, however, adds the crucial element of increased pressure. This pressure dramatically increases the amount of oxygen that can be carried by the blood plasma, not just the red blood cells. This allows oxygen to reach areas that might be inaccessible through normal blood flow alone, such as in damaged brain tissue or areas affected by swelling. The unique combination of high oxygen concentration and increased pressure is what sets HBOT apart and contributes to its distinct therapeutic effects.
Conditions Under Investigation for HBOT
While our focus here is on chronic pain and conditions like fibromyalgia, HBOT is being studied for a wide array of medical issues. For instance, research has looked into its efficacy and safety for acute ischaemic stroke (AIS). A meta-analysis included 8 studies with 493 patients to evaluate HBOT as an adjunctive therapy for AIS HBOT efficacy in acute ischaemic stroke. Although it did not show statistically significant differences in some outcomes like NIHSS score or Barthel index, it did show significant improvement in modified Rankin score, suggesting functional benefits. Furthermore, ongoing trials, such as NCT02407028, are specifically investigating HBOT for persistent symptoms after traumatic brain injury, highlighting the continued interest in its neurological applications Clinical trial for traumatic brain injury. The potential for HBOT to impact conditions involving tissue hypoxia or inflammation makes it a subject of continuous scientific inquiry.
The Role of HBOT in Healing and Recovery
The enhanced oxygen delivery during HBOT can support several physiological processes crucial for healing. It can stimulate the growth of new blood vessels, reduce swelling and inflammation, and activate cells that promote tissue repair. For conditions involving chronic pain, these mechanisms could potentially help by improving blood flow to affected areas, reducing nerve inflammation, and supporting the regeneration of damaged tissues. The ability of HBOT to reach deeper tissues with oxygen also makes it a compelling area of study for conditions where traditional treatments have limited success, particularly those involving complex physiological changes. The research continues to explore these pathways to better understand how HBOT can be most effectively applied to improve patient outcomes.
Can HBOT Help with PTSD Symptoms and Associated Pain?
Yes, hyperbaric oxygen therapy (HBOT) has shown promise in helping with PTSD symptoms, which often include elements of chronic pain. A systematic review of HBOT treatment for PTSD symptoms found statistically significant improvements and reliable or clinically significant changes in patients. These positive outcomes were observed in individuals who received 40-60 HBOT treatments, with pressures ranging from 1.3 to 2.0 ATA. The symptomatic improvements were further supported by observable changes in functional and anatomic brain imaging in three of the included studies, suggesting a tangible impact on brain function and structure.
Evidence from Systematic Reviews
In our analysis of the available research, a systematic review published in Front Neurol. 2024, by Susan R Andrews et al., specifically looked at HBOT's efficacy in treating post-traumatic stress disorder Systematic review of HBOT for PTSD. This review included eight studies, with a total of 393 subjects. Seven of these were randomized trials, and one was an imaging case-controlled study. The subjects in these studies were diverse, ranging from 3 to 450 months post-trauma, encompassing both military and civilian populations. The consistent finding across these studies was that HBOT led to statistically significant symptomatic improvements.
Dosage and Response Relationship
A critical finding from this systematic review was the identification of a linear dose-response relationship. This means that as the cumulative oxygen dose increased, so did the symptomatic improvement. The effective cumulative oxygen doses ranged from 1002 to 11,400 atmosphere-minutes of oxygen. This suggests that the total amount of oxygen delivered over time plays a crucial role in the therapeutic outcome. Patients receiving higher cumulative doses experienced greater relief from their PTSD symptoms. This data provides valuable insight into potential treatment protocols, indicating that a certain threshold or range of total oxygen exposure might be necessary to achieve optimal benefits.
Side Effects and Safety Profile
While the benefits were significant, the review also highlighted an important safety consideration. At the highest oxygen doses, 30-39% of subjects experienced a severe but reversible exacerbation of emotional symptoms. This is a crucial piece of information for practitioners and patients considering HBOT, as it suggests that while higher doses may lead to greater improvement, they also carry a higher risk of temporary emotional distress. Outside of this, other side effects reported were generally transient and minor. The fact that these emotional exacerbations were reversible is reassuring, but it underscores the need for careful monitoring and individualized dosage adjustments during treatment.
Corroborating Evidence from Brain Imaging
The symptomatic improvements observed in patients were not just subjective. In three of the studies included in the review, these improvements were associated with functional and anatomic brain imaging changes. This is a powerful finding because it provides objective evidence that HBOT is having a measurable impact on the brain. These changes in brain regions affected by PTSD suggest that the therapy is addressing underlying physiological mechanisms, rather than just masking symptoms. The imaging findings, along with the observed effects of hyperbaric oxygen therapy, led the researchers to conclude that PTSD can no longer be considered strictly a psychiatric disease. This statement from Susan R Andrews et al. in Front Neurol. 2024, emphasizes a paradigm shift in understanding PTSD, moving towards a recognition of its neurobiological underpinnings and the potential for physiological treatments like HBOT.
Implications for Chronic Pain
Given the strong link between PTSD and chronic pain, these findings have significant implications. Many individuals with PTSD experience chronic pain as a co-occurring condition, and the mechanisms by which HBOT improves PTSD symptoms—such as reducing inflammation, improving brain blood flow, and promoting tissue repair—could also directly impact pain pathways. While the review specifically focused on PTSD, the observed brain changes and symptomatic improvements offer a compelling rationale for further investigation into HBOT's role in chronic pain conditions that often accompany trauma-related disorders. The ability to achieve reliable and clinically significant changes in such a complex condition makes HBOT a promising area for continued research in the broader field of chronic pain management.
How Does HBOT Affect the Brain in Trauma-Related Conditions?
Hyperbaric oxygen therapy (HBOT) affects the brain in trauma-related conditions by inducing functional and microstructural changes in affected regions, moving beyond a purely psychiatric understanding of conditions like PTSD. The symptomatic improvements seen with HBOT are directly supported by these observable alterations in brain imaging. This suggests that HBOT is not merely alleviating symptoms but is actively influencing the physiological landscape of the brain, potentially addressing the root causes of trauma-related neurological dysfunction.
Imaging Evidence of Brain Changes
When we look at the results from studies involving HBOT for conditions like PTSD, the evidence points to more than just subjective symptom relief. Correlative functional and microstructural imaging changes were observed in PTSD-affected brain regions in three of the studies reviewed by Susan R Andrews et al. in Front Neurol. 2024 Systematic review of HBOT for PTSD. This means that alongside patients reporting feeling better, their brain scans showed measurable differences. These changes could include improved blood flow, reduced inflammation, or even the repair of neural pathways. Such objective evidence is crucial because it helps us understand the physiological impact of HBOT on the central nervous system. It indicates that the therapy is influencing the brain at a cellular or tissue level, rather than just providing a psychological effect.
Reclassifying PTSD: Beyond a Psychiatric Disorder
The imaging findings, coupled with the observed effects of hyperbaric oxygen therapy, have led experts to propose a significant re-evaluation of how PTSD is understood. According to Susan R Andrews et al., "The imaging findings and hyperbaric oxygen therapy effects indicate that PTSD can no longer be considered strictly a psychiatric disease." This statement is profound. It suggests that PTSD, traditionally viewed as a purely mental health condition, has strong physiological and neurological components that can be targeted and potentially healed by physical interventions like HBOT. This shift in perspective opens new avenues for treatment development, focusing on neurobiological repair and functional restoration rather than solely on psychological coping mechanisms.
Mechanisms of Brain Repair and Function
The exact mechanisms by which HBOT induces these brain changes are complex but are thought to involve several key processes. The increased oxygen dissolved in the blood can reduce cerebral edema (brain swelling), decrease inflammation, and improve mitochondrial function—the energy powerhouses of cells. It can also stimulate angiogenesis, the growth of new blood vessels, which can improve blood supply to damaged or under-perfused brain areas. Additionally, HBOT may promote neurogenesis (the birth of new neurons) and glial cell function, both essential for brain health and repair. For individuals with trauma-related brain injuries or conditions, these processes could lead to improved cognitive function, reduced emotional dysregulation, and a decrease in associated physical symptoms, including chronic pain.
Implications for Fibromyalgia and Chronic Pain
While the research directly cited focuses on PTSD and traumatic brain injury, the implications for fibromyalgia and other chronic pain conditions are significant. Many chronic pain syndromes, including fibromyalgia, are increasingly understood to involve central nervous system sensitization, neuroinflammation, and altered brain function. If HBOT can induce positive changes in brain structure and function in PTSD, it suggests a potential pathway for similar benefits in other conditions rooted in neurological dysfunction. By improving oxygen delivery and promoting neuroplasticity, HBOT could help reset dysfunctional pain processing pathways in the brain, reduce systemic inflammation, and improve overall neurological resilience, offering hope for patients struggling with chronic, intractable pain.
Ongoing Research and Future Directions
The understanding of HBOT's effects on the brain is still evolving. Ongoing clinical trials, such as the Hyperbaric Oxygen Brain Injury Treatment Trial (NCT02407028), continue to investigate its role in conditions like traumatic brain injury Clinical trial for traumatic brain injury. These studies aim to further elucidate the precise mechanisms and optimal treatment protocols. As we gather more data, we anticipate a clearer picture of how HBOT can be best utilized to support brain health and recovery in a wide range of trauma-related and chronic neurological conditions, ultimately improving the quality of life for affected individuals. The shift in perspective regarding PTSD, fueled by HBOT research, underscores the importance of exploring physical therapies for conditions once thought to be purely psychological.
Is HBOT Safe for Treating Neurological Conditions?
Overall, HBOT appears to be safe for treating neurological conditions, with side effects generally being transient and minor, though some specific risks exist at higher doses. In studies investigating HBOT for PTSD, side effects were mostly minor, with the notable exception of a severe but reversible exacerbation of emotional symptoms in 30-39% of subjects at the highest oxygen doses. For acute ischaemic stroke, a meta-analysis found no statistically significant difference in adverse event incidence within ≤ 6 months of follow-up between HBOT and control groups. However, HBOT did show a significant improvement in adverse event incidence at the end of treatment for stroke patients, with an odds ratio of 0.42 (95% CI = 0.19 to 0.94) HBOT efficacy in acute ischaemic stroke. This suggests a favorable safety profile in some contexts.
Safety Profile in PTSD Studies
When we reviewed the systematic analysis of HBOT for PTSD, the safety data was generally positive. Across the eight studies included, side effects were consistently described as transient and minor. This means they were temporary and not severe, usually resolving on their own without lasting impact. However, a significant observation was made regarding the highest oxygen doses. In 30-39% of subjects receiving these higher doses, there was a severe, but importantly, reversible exacerbation of emotional symptoms Systematic review of HBOT for PTSD. This specific side effect, while temporary, highlights the importance of careful patient selection, monitoring, and potentially dose adjustment, especially when using more aggressive treatment protocols. It underscores that while HBOT is generally well-tolerated, it is not without potential acute reactions that need to be managed by experienced practitioners.
Quality of Research and Methodological Rigor
The reliability of safety data is directly linked to the quality of the studies from which it is derived. In the case of HBOT for PTSD, all seven randomized trials included in the systematic review were found to be of good-highest quality by the PEDro scale scoring. The PEDro scale is a recognized tool for assessing the methodological quality of randomized controlled trials. This high rating means that the studies were well-designed and executed, minimizing bias and increasing confidence in their findings, including those related to safety. Knowing that the evidence comes from high-quality trials strengthens our understanding of HBOT's safety profile in this specific application.
Safety in Acute Ischaemic Stroke (AIS)
Moving to another neurological condition, acute ischaemic stroke (AIS), a systematic review and meta-analysis specifically evaluated the efficacy and safety of adjunctive HBOT. This analysis included 8 studies involving 493 patients. When comparing HBOT to control groups (no HBOT or sham HBOT), the meta-analysis found no statistically significant differences in adverse event incidence within a follow-up period of up to 6 months. This suggests that over a medium-term period, HBOT did not increase the overall risk of adverse events compared to standard care.
Interestingly, the review also reported a significant improvement in adverse event incidence at the end of treatment for the HBOT group compared to the control group. The odds ratio (OR) was 0.42, with a 95% confidence interval of 0.19 to 0.94 HBOT efficacy in acute ischaemic stroke. An OR less than 1 suggests a reduced risk of adverse events. This particular finding could indicate that HBOT, when used in the acute phase of stroke, might actually help mitigate some immediate treatment-related complications or contribute to a more stable post-treatment recovery phase, at least in terms of adverse events. This is a crucial point for patient safety in a vulnerable population.
General Considerations for HBOT Safety
Beyond specific neurological conditions, general safety considerations for HBOT include barotrauma (injury due to pressure changes) to the ears or sinuses, temporary changes in vision, and claustrophobia in the chamber. Oxygen toxicity, which can affect the lungs or central nervous system, is a rare but serious risk, typically associated with very high pressures or prolonged exposures. However, in the treatment protocols studied for PTSD and stroke, these severe complications were not highlighted as major concerns, suggesting that the pressures and durations used in these therapeutic settings are generally well within safe limits for most patients. Close medical supervision and adherence to established protocols are always paramount to ensure patient safety during HBOT.
The Importance of Qualified Supervision
Given the potential for specific side effects, especially at higher oxygen doses, it is critical that HBOT is administered under the supervision of qualified medical professionals. These professionals can assess patient suitability, monitor for adverse reactions, and adjust treatment parameters as needed. The generally good safety profile reported in high-quality randomized trials for neurological conditions like PTSD and acute ischaemic stroke is encouraging, but it always presumes that the therapy is delivered in a controlled and expert-guided environment. Patients considering HBOT should always discuss the potential benefits and risks thoroughly with their healthcare provider.
What About HBOT for Acute Ischaemic Stroke (AIS)?
Hyperbaric oxygen therapy (HBOT) has been investigated as an adjunctive treatment for acute ischaemic stroke (AIS), with a systematic review and meta-analysis providing valuable insights. This comprehensive analysis, which included 8 studies and a total of 493 patients, aimed to evaluate both the efficacy and safety of HBOT in this critical neurological condition. While HBOT did not show statistically significant differences in some widely used stroke outcome measures, it did demonstrate a significant improvement in the modified Rankin score, indicating potential functional benefits for stroke patients.
Findings from the Meta-Analysis
The systematic review and meta-analysis, published in BMC Neurol. 2024 by Xuezheng Li et al., focused on randomized controlled trials (RCTs) comparing adjunctive HBOT with non-HBOT or sham HBOT treatments for AIS HBOT efficacy in acute ischaemic stroke. The researchers conducted a thorough search across seven major databases up to April 15, 2023, to gather the most relevant and high-quality evidence. The results showed a mixed picture regarding various outcome measures.
Specifically, the meta-analysis found no statistically significant differences between the HBOT group and the control group for several key indicators:
- NIHSS score (National Institutes of Health Stroke Scale): This score measures stroke severity. The mean difference (MD) was -1.41, with a 95% confidence interval (CI) of -7.41 to 4.58. Since the CI crosses zero, there was no significant difference.
- Barthel index: This index assesses daily living activities. The MD was 8.85, with a 95% CI of -5.84 to 23.54, again indicating no significant difference.
- Inflammatory markers: The study also looked at markers such as TNF-α (MD = -5.78, 95%CI = -19.93 to 8.36), sICAM (MD = -308.47, 95%CI = -844.13 to 13227.19), sVCAM (MD = -122.84, 95%CI = -728.26 to 482.58), sE-selectin (MD = 0.11, 95%CI = -21.86 to 22.08), and CRP (MD = -5.76, 95%CI = -15.02 to 3.51). For all these inflammatory markers, no statistically significant differences were found between the HBOT and control groups.
These findings suggest that, based on the analyzed studies, HBOT may not significantly alter the acute severity of stroke or the immediate capacity for daily activities, nor does it appear to have a broad impact on the measured systemic inflammatory responses in the context of AIS.
Significant Improvement in Modified Rankin Score
Despite the lack of significant differences in some measures, HBOT did show a crucial positive outcome: a significant improvement in the modified Rankin score (mRS). The mRS is a widely used scale for measuring the degree of disability or dependence in daily activities of people who have suffered a stroke or other causes of neurological disability. A lower score indicates less disability. The meta-analysis reported an MD of 0.10, with a 95% CI of 0.03 to 0.17, for the modified Rankin score. This statistically significant improvement suggests that patients receiving adjunctive HBOT experienced better functional outcomes or less disability compared to those in the control group. This is a very important finding because functional recovery is a primary goal in stroke rehabilitation.
Adverse Event Incidence
Regarding safety, the meta-analysis found no statistically significant differences between HBOT and the control group in terms of adverse event incidence within a follow-up period of up to 6 months (OR = 0.98, 95%CI = 0.25 to 3.79). This indicates that HBOT did not increase the overall risk of adverse events in the longer term.
Furthermore, HBOT showed a significant improvement in adverse event incidence specifically at the end of treatment, with an odds ratio of 0.42 (95%CI = 0.19 to 0.94) compared to the control group. An odds ratio below 1 suggests that the HBOT group had a lower risk of experiencing adverse events immediately following the treatment period. This could imply that HBOT might have protective effects or contribute to a more stable physiological state during the immediate post-treatment phase in AIS patients.
Implications for Stroke Treatment
The findings from this meta-analysis suggest that while HBOT may not be a silver bullet for all aspects of acute ischaemic stroke recovery, its potential to improve functional outcomes, as indicated by the modified Rankin score, is noteworthy. The favorable safety profile, particularly the reduced incidence of adverse events at the end of treatment, further supports its consideration as a potential adjunctive therapy. However, more research is needed to define optimal treatment protocols, patient selection criteria, and to understand the mechanisms behind the observed functional improvements. For patients and clinicians, these results provide a basis for continued exploration of HBOT as part of a comprehensive stroke management strategy.
Are There Ongoing Trials for Brain Injury and HBOT?
Yes, there are ongoing clinical trials specifically investigating the use of hyperbaric oxygen therapy (HBOT) for brain injuries. One notable example is the Hyperbaric Oxygen Brain Injury Treatment Trial, registered as NCT02407028 on ClinicalTrials.gov Clinical trial for traumatic brain injury. This randomized clinical trial is designed to test whether HBOT can effectively reduce persistent symptoms that occur after a traumatic brain injury (TBI) when compared to an inactive, or placebo, HBOT treatment. Such trials are crucial for establishing robust evidence for HBOT's efficacy and safety in this specific patient population.
The Hyperbaric Oxygen Brain Injury Treatment Trial (NCT02407028)
This particular trial focuses on individuals who have experienced mild or moderate traumatic brain injury or concussion. A key eligibility criterion is that the injury or concussion exposure must have occurred at least one year prior to participation. This focus on chronic symptoms after TBI is important because many patients continue to suffer from persistent issues long after the initial injury has healed. The study aims to provide answers for those living with long-term effects. The trial is specifically recruiting U.S. Service Members, Veterans, and Active-Duty Military personnel, aged 18-75 years. This demographic is often at a higher risk for TBIs due to their service, making the research highly relevant to their health and well-being. The approximate duration of participation in this trial is about 4 months, allowing for a comprehensive assessment of HBOT's impact over a meaningful period.
Design of Randomized Clinical Trials
Randomized clinical trials (RCTs) like NCT02407028 are considered the gold standard in medical research for determining the effectiveness of an intervention. In this trial, participants are randomly assigned to either receive active HBOT or a placebo HBOT. A placebo HBOT typically involves a chamber pressurization to a minimal level (e.g., slightly above sea level) with normal air, so participants experience the chamber environment but do not receive the therapeutic dose of pure oxygen at higher pressure. This design helps to control for the placebo effect, ensuring that any observed improvements can be attributed directly to the HBOT itself, rather than to the expectation of treatment. The double-blind nature of such trials, where neither the participants nor the researchers know who is receiving which treatment, further enhances the integrity of the results. This rigorous approach is essential for providing concrete evidence about HBOT's role in TBI recovery.
Why Focus on Chronic TBI Symptoms?
The decision to focus on individuals with TBI or concussion exposure at least one year prior highlights the significant challenge of persistent post-concussion syndrome. Many individuals experience a range of debilitating symptoms, including headaches, dizziness, fatigue, cognitive difficulties, and mood disturbances, which can severely impact their quality of life for years after the initial injury. Current treatments for these chronic symptoms are often limited, making the exploration of new therapies like HBOT critically important. By studying HBOT in this context, researchers hope to identify a treatment that can address the underlying physiological changes that contribute to these long-lasting symptoms. The brain's capacity for repair, even years after injury, is a key area of interest, and HBOT's ability to promote healing and reduce inflammation makes it a strong candidate for investigation.
Broader Implications for Chronic Neurological Conditions
The outcomes of trials like NCT02407028 will not only be vital for TBI patients but could also have broader implications for other chronic neurological conditions that share similar pathological features, such as neuroinflammation or impaired cerebral blood flow. For instance, if HBOT proves effective in improving chronic TBI symptoms, it could inform future research into its application for conditions like fibromyalgia or other chronic pain syndromes where brain dysfunction and neuroinflammation are implicated. The rigorous methodology of these trials is essential for building a strong evidence base that can guide clinical practice and help patients make informed decisions about their treatment options. The ongoing commitment to research in this area underscores the scientific community's dedication to finding effective solutions for complex neurological challenges.
Frequently Asked Questions
What conditions has HBOT shown promise for?
HBOT has shown promise for conditions such as post-traumatic stress disorder (PTSD) and acute ischaemic stroke (AIS). For PTSD symptoms, a systematic review found significant improvements in patients treated with 40-60 HBOT sessions Systematic review of HBOT for PTSD. In acute ischaemic stroke, a meta-analysis of 8 studies involving 493 patients indicated that HBOT significantly improved the modified Rankin score, which measures functional disability HBOT efficacy in acute ischaemic stroke. Ongoing trials are also investigating its effectiveness for chronic traumatic brain injury symptoms.
How many HBOT sessions are typically needed for PTSD symptoms?
Based on a systematic review, patients with PTSD symptoms achieved statistically significant improvements and clinically significant changes after receiving 40-60 HBOT treatments Systematic review of HBOT for PTSD. These sessions were administered over a wide range of pressures, from 1.3 to 2.0 ATA. The research also found a linear dose-response relationship, where increased symptomatic improvement correlated with higher cumulative oxygen doses, ranging from 1002 to 11,400 atmosphere-minutes of oxygen.
Are there any significant side effects of HBOT?
HBOT generally has transient and minor side effects. However, in studies for PTSD, 30-39% of subjects experienced a severe but reversible exacerbation of emotional symptoms at the highest oxygen doses Systematic review of HBOT for PTSD. For acute ischaemic stroke, a meta-analysis showed no statistically significant increase in adverse events within 6 months of follow-up compared to control groups. In fact, HBOT was associated with a significant improvement in adverse event incidence at the end of treatment (OR = 0.42, 95%CI = 0.19 to 0.94) for stroke patients.
Does HBOT help with brain function after trauma?
Yes, HBOT has shown to help with brain function after trauma. In three studies on PTSD, symptomatic improvements were associated with correlative functional and anatomic brain imaging changes in affected brain regions Systematic review of HBOT for PTSD. These findings suggest that HBOT influences the physiological aspects of the brain, leading researchers to state that PTSD may no longer be considered strictly a psychiatric disease. Ongoing trials, such as NCT02407028, are further exploring HBOT's ability to reduce persistent symptoms after traumatic brain injury Clinical trial for traumatic brain injury.
Is HBOT currently an FDA-approved treatment for fibromyalgia or chronic pain?
The provided research does not directly address FDA approval for fibromyalgia or chronic pain. The studies focus on conditions like PTSD, acute ischaemic stroke, and traumatic brain injury. While HBOT has shown promise in these areas, particularly in improving PTSD symptoms and functional outcomes in stroke, its application for fibromyalgia and general chronic pain is still an area requiring further dedicated research and clinical trials to establish efficacy and gain specific regulatory approvals.
--- The HBOT Finder Team